מירסרה 75 מקג 0.3 מל ישראל - עברית - Ministry of Health

מירסרה 75 מקג 0.3 מל

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - תמיסה להזרקה - methoxy polyethylene glycol-epoetin beta 75 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

מירסרה 100 מקג 0.3 מל ישראל - עברית - Ministry of Health

מירסרה 100 מקג 0.3 מל

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - תמיסה להזרקה - methoxy polyethylene glycol-epoetin beta 100 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

מירסרה 150 מקג 0.3 מל ישראל - עברית - Ministry of Health

מירסרה 150 מקג 0.3 מל

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - תמיסה להזרקה - methoxy polyethylene glycol-epoetin beta 150 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

מירסרה 200 מקג 0.3 מל ישראל - עברית - Ministry of Health

מירסרה 200 מקג 0.3 מל

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - תמיסה להזרקה - methoxy polyethylene glycol-epoetin beta 200 mcg / 0.3 ml - methoxy polyethylene glycol-epoetin beta - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

אלונבה 100 מקג  0.5 מל ישראל - עברית - Ministry of Health

אלונבה 100 מקג 0.5 מל

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

אלונבה 150 מקג  0.5 מל ישראל - עברית - Ministry of Health

אלונבה 150 מקג 0.5 מל

organon pharma israel ltd., israel - corifollitropin alfa - תמיסה להזרקה - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

צפוויט פורטה תרחיף ישראל - עברית - Ministry of Health

צפוויט פורטה תרחיף

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - אבקה להכנת תרחיף - cefalexin as monohydrate 250 mg / 5 ml - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט 250 ישראל - עברית - Ministry of Health

צפוויט 250

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 250 mg - cefalexin - cefalexin - antibiotic for the treatment of infections caused by micro-organisms sensitive to cephalexin.

צפוויט פורטה 500 ישראל - עברית - Ministry of Health

צפוויט פורטה 500

vitamed pharmaceutical industries ltd - cefalexin as monohydrate - קפסולות - cefalexin as monohydrate 500 mg - cefalexin - cefalexin - treatment of infections caused by cephalexin susceptible microorganisms.

קייליקס ישראל - עברית - Ministry of Health

קייליקס

j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.